新药作为主要治疗的多发性骨髓瘤患者中修订版国际分期系统的综合评估
该回顾性分析纳入514例以沙利度胺、硼替佐米和来那度胺等新药作为主要治疗的新诊断多发性骨髓瘤患者,评估修订版国际分期系统(R-ISS)的区分能力和对国际分期系统(ISS)患者的重新分类能力。中位随访42.3个月,R-ISS各期中位总生存期差异显著(P<0.001),R-ISS的C统计量显著大于ISS(0.769 vs. 0.696,P<0.001),但总NRI为-0.03(95%CI -0.14-0.08,P=0.602),未能更好地重新分类患者。
要点
- R-ISS各期中位总生存期差异显著(P<0.001)。
- R-ISS的C统计量显著大于ISS(0.769 vs. 0.696,P<0.001)。
- 总NRI为-0.03(95%CI -0.14-0.08,P=0.602),未改善重新分类。
核心结论
- R-ISS在新药作为主要治疗的多发性骨髓瘤患者中表现良好,区分能力显著优于ISS。
- R-ISS未能更好地从ISS重新分类患者,提示分期系统仍有改进空间。
- 未来研究需要新的统计方法来评估和量化新预后模型的风险预测。
研究设计与样本
- 回顾性分析纳入514例以沙利度胺、硼替佐米和来那度胺等新药作为主要治疗的新诊断多发性骨髓瘤患者。
- 中位随访42.3个月(范围40.5-44.1个月)。
主要发现
- 中位总生存期为61.0个月。
- R-ISS 1、2、3期的中位总生存期分别为未达到、60.9个月和50.1个月,三期差异显著(P<0.001)。
- R-ISS的C统计量显著大于ISS(0.769 vs. 0.696,P<0.001)。
- 事件NRI为-0.08(95%CI -0.18-0.01),非事件NRI为0.05(95%CI -0.03-0.10),总NRI为-0.03(95%CI -0.14-0.08,P=0.602)。
关键数值与推荐
- R-ISS 1、2、3期的中位总生存期分别为未达到、60.9个月和50.1个月(P<0.001)。
- R-ISS的C统计量为0.769,ISS的C统计量为0.696(P<0.001)。
- 总NRI为-0.03(95%CI -0.14-0.08,P=0.602)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The revised International Staging System (R-ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over the ISS. We assessed the R-ISS in MM patients who were treated with novel agents as a primary therapy and evaluated its discriminative power and ability to reclassify patients from the ISS. A total of 514 newly diagnosed MM patients treated with novel agents including thalidomide, bortezomib, and lenalidomide as a primary therapy were included in this retrospective analysis. With a median follow-up duration of 42.3 months (range, 40.5-44.1), the median overall survival (OS) was 61.0 months. There was a significant difference in median OS (not reached, 60.9, and 50.1 months for stages 1, 2, and 3, respectively, P < 0.001) among the three stages of R-ISS. The C-statistic was significantly greater for R-ISS than for ISS (0.769 vs. 0.696, P < 0.001). The event NRI was -0.08 (95% confidence interval [CI], -0.18-0.01) and the non-event NRI was 0.05 (95% CI, -0.03-0.10), resulting in a total NRI of -0.03 (95% CI, -0.14-0.08, P = 0.602). The R-ISS performs well and has significantly better discriminative power than the ISS in MM patients treated with novel agents as a primary therapy. However, it does not better reclassify patients from the ISS, suggesting that there is still room to improve the staging system. Moreover, new statistical measures for assessing and quantifying the risk prediction of new prognostic models are necessary in future studies.
引用
- Cho H, Yoon DH, Lee JB, et al. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol. 2017. PMID: 28833417. doi:10.1002/ajh.24891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。